Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS: Sarilumab with ICI Rechallenge in Advanced Solid Tumors
NCT07836101Phase 2Not yet recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
A Phase 2 trial of sarilumab in immune-related adverse event (irAE), sponsored by Sidney Kimmel Comprehensive Cancer Center. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
sarilumab
03
Conditions
immune-related adverse event (irAE)
Beyond the preview
Go deeper on NCT07836101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07836101.